{"id":391527,"date":"2026-01-06T10:32:10","date_gmt":"2026-01-06T10:32:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/391527\/"},"modified":"2026-01-06T10:32:10","modified_gmt":"2026-01-06T10:32:10","slug":"new-50-million-centre-aims-to-shake-up-clinical-trials-in-the-uk-news","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/391527\/","title":{"rendered":"New \u00a350 million centre aims to shake up clinical trials in the UK | News"},"content":{"rendered":"<p class=\"picture\"><img fetchpriority=\"high\" decoding=\"async\" alt=\"A medical professional with a tray of blood samples and a test subject behind holding a dressing to her arm where she has had a blood sample taken.\" src=\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2026\/01\/544678_wc_15_12_shutterstock_2273133101_622056.jpg\"  loading=\"eager\" class=\"lazyloaded\" width=\"3000\" height=\"2000\"\/><\/p>\n<p>A new \u00a350 million initiative aims to cut the length of time novel medicines spend in clinical trials, enabling patients to benefit from new treatments much sooner.<\/p>\n<p>The UK\u2019s Medical Research Council Centre of Research Excellence in Clinical Trial Innovation (MRC CoRE CTI), which is being set up in partnership with the National Institute for Health and Care Research, will receive \u00a350 million over 14 years with the ambition of transforming the clinical trial landscape. The leadership group for MRC CoRE includes researchers from six UK universities: University College London, London School of Hygiene &amp; Tropical Medicine, University of Cambridge, University of Edinburgh, University of Birmingham and Newcastle University.<\/p>\n<p>The centre will build on the work of the MRC Clinical Trials Unit, which developed \u2018<a href=\"https:\/\/www.mrcctu.ucl.ac.uk\/our-research\/methodology\/design\/multi-arm-multi-stage-mams-platform-trials\/\" rel=\"nofollow noopener\" target=\"_blank\">multi-arm multi-stage<\/a>\u2019 (MAMS) trial design. Unlike traditional designs, MAMS allows researchers to test multiple treatment arms at the same time and also gives them the ability to drop treatments that don\u2019t show promise and add new ones as they become available.<\/p>\n<p>The MAMS design has already been used in over 80 published trials and provides several advantages, including the ability to test new treatments faster and reduce costs, as it removes the need to set up a new trial for each new treatment available.<\/p>\n<p>The new MRC CoRE CTI plans to shake-up approaches to clinical trial design and delivery by developing pioneering new ways to speed up the process and drive improvements in treatment and recovery. It will offer various projects, including MAMS, non-inferiority trials, which test whether a treatment is only marginally better than the current best, and personalised randomised controlled trials.<\/p>\n<p>\u2018Clinical trials are vital for turning promising research into real treatments, but they often take a long time,\u2019 said science minister, Patrick Vallance, in a <a title=\"Groundbreaking \u00a350m MRC centre will overhaul clinical trials\" href=\"https:\/\/www.ukri.org\/news\/groundbreaking-50m-mrc-centre-will-overhaul-clinical-trials\/\" rel=\"nofollow noopener\" target=\"_blank\">statement published on 18 December<\/a>. \u2018By investing \u00a350 million in this new centre, we\u2019re helping to speed up the process so patients can access life-changing medicines sooner, with a process that is as rigorous.\u2019<\/p>\n<p>One of the centre\u2019s key areas of focus will be to move away from the current approach of testing a single intervention in a single disease one at a time and instead move to new, efficient ways to test multiple drugs in multiple diseases simultaneously.<\/p>\n<p>Another significant area of focus is using clinical trials to identify minimum \u2018intensity\u2019 for medicines, meaning the lowest duration, frequency or dose required for a drug to be effective. This approach could help make certain treatments, such as chemotherapy, less taxing for patients by reducing side effects.<\/p>\n","protected":false},"excerpt":{"rendered":"A new \u00a350 million initiative aims to cut the length of time novel medicines spend in clinical trials,&hellip;\n","protected":false},"author":2,"featured_media":391528,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[49,48,61],"class_list":["post-391527","post","type-post","status-publish","format-standard","has-post-thumbnail","category-technology","tag-ca","tag-canada","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/391527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=391527"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/391527\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/391528"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=391527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=391527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=391527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}